NSCLC
EMA panel recommends label extension of AstraZeneca’s Imfinzi in non-small cell lung cancer
December 15, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, Europe, Imfinzi, NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed a new dosing regimen of AstraZeneca’s …
Roche’s Tecentriq combo scores FDA approval in non-small cell lung cancer
December 4, 2019Research and Development, Sales and Marketing FDA, NSCLC, Roche, pharma, tecentriq
Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane …
AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer
October 29, 2019Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma
AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …
BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer
October 23, 2019Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …
Roche’s Tecentriq combo recommended in Europe for non-small cell lung cancer
July 29, 2019Sales and Marketing Cancer, NSCLC, Roche, lung cancer, pharma, tecentriq
Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was …
BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer
July 25, 2019Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …
Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua
May 8, 2019Research and Development Cancer, Europe, Lorviqua, NSCLC, Pfizer, lung cancer, pharma
Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …
MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer
March 15, 2019Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …
Roche’s Tecentriq combo scoops up European approval in first-line metastatic lung cancer
March 8, 2019Medical Communications, Sales and Marketing Cancer, Europe, European Commission, NSCLC, Roche, lung cancer, pharma
Roche has announced the approval of the European Commission for its PD-L1 inhibitor Tecentriq (atezolizumab) when used in combination with …
J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn
November 6, 2018Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea
Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal …
MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer
November 1, 2018Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …
Roche’s entrectinib shrinks lung tumours with two-year response duration
September 25, 2018Manufacturing and Production, Research and Development, Sales and Marketing Cancer, NSCLC, NSCLC< lung cancer, Roche, entrectinib
Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive …
AstraZeneca chalks up European approval for Imfinzi in locally advanced, unresectable lung cancer
September 25, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MedImmune, NSCLC, lung cancer, pharma
AstraZeneca and its global biologics R&D arm MedImmune have announced the approval by the European Commission of Imfinzi (durvalumab) as …
Keytruda scores ground-breaking European approval in lung cancer subgroup
September 10, 2018Sales and Marketing Cancer, EU, Europe, MSD, Merck, NSCLC, keytruda, lung cancer, pharma
Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …
Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer
July 27, 2018Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma
Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …
Latest content
Five Facts about cardiovascular disease
